BACKGROUND: Behavioral and psychological signs and symptoms of dementia (BPSD) are a heterogeneous group of behavioral and psychiatric disturbances occurring in dementia patients of any etiology. Research suggests that altered activities of dopaminergic, serotonergic, (nor)adrenergic, as well as amino acid neurotransmitter systems play a role in the etiopathogenesis of BPSD. In this study we attempted to identify cerebrospinal fluid (CSF) neurochemical correlates of BPSD to provide further insight into its underlying neurochemical pathophysiological mechanisms. METHODS: Patients with probable Alzheimer's disease (AD; n = 202), probable AD with cerebrovascular disease (n = 37), probable frontotemporal dementia (FTD; n = 32), and probable dementia with Lewy bodies (DLB; n = 26) underwent behavioral assessment and lumbar puncture. CSF levels of six amino acids and several biogenic amines and metabolites were analyzed using ultraperformance liquid chromatography with fluorescence detection and reversed-phase high-performance liquid chromatography with fluorescence detection. RESULTS: In the AD patients, CSF homovanillic acid/5-hydroxyindoleacetic acid (HVA/5HIAA) ratios correlated positively with anxieties/phobias, whereas CSF levels of taurine correlated negatively with depression and behavioral disturbances in general. In FTD patients, CSF levels of glutamate correlated negatively with verbally agitated behavior. In DLB patients, CSF levels of HVA correlated negatively with hallucinations. CONCLUSIONS: Several neurotransmitter systems can be linked to one specific behavioral syndrome depending on the dementia subtype. In addition to biogenic amines and metabolites, amino acids seem to play a major role in the neurochemical etiology of BPSD as well.
BACKGROUND: Behavioral and psychological signs and symptoms of dementia (BPSD) are a heterogeneous group of behavioral and psychiatric disturbances occurring in dementiapatients of any etiology. Research suggests that altered activities of dopaminergic, serotonergic, (nor)adrenergic, as well as amino acid neurotransmitter systems play a role in the etiopathogenesis of BPSD. In this study we attempted to identify cerebrospinal fluid (CSF) neurochemical correlates of BPSD to provide further insight into its underlying neurochemical pathophysiological mechanisms. METHODS:Patients with probable Alzheimer's disease (AD; n = 202), probable AD with cerebrovascular disease (n = 37), probable frontotemporal dementia (FTD; n = 32), and probable dementia with Lewy bodies (DLB; n = 26) underwent behavioral assessment and lumbar puncture. CSF levels of six amino acids and several biogenic amines and metabolites were analyzed using ultraperformance liquid chromatography with fluorescence detection and reversed-phase high-performance liquid chromatography with fluorescence detection. RESULTS: In the ADpatients, CSF homovanillic acid/5-hydroxyindoleacetic acid (HVA/5HIAA) ratios correlated positively with anxieties/phobias, whereas CSF levels of taurine correlated negatively with depression and behavioral disturbances in general. In FTDpatients, CSF levels of glutamate correlated negatively with verbally agitated behavior. In DLB patients, CSF levels of HVA correlated negatively with hallucinations. CONCLUSIONS: Several neurotransmitter systems can be linked to one specific behavioral syndrome depending on the dementia subtype. In addition to biogenic amines and metabolites, amino acids seem to play a major role in the neurochemical etiology of BPSD as well.
Authors: Yannick Vermeiren; Debby Van Dam; Tony Aerts; Sebastiaan Engelborghs; Jean-Jacques Martin; Peter P De Deyn Journal: Alzheimers Res Ther Date: 2015-02-11 Impact factor: 6.982
Authors: Alain D Dekker; Silvia Sacco; Angelo Carfi; Bessy Benejam; Yannick Vermeiren; Gonny Beugelsdijk; Mieke Schippers; Lyanne Hassefras; José Eleveld; Sharina Grefelman; Roelie Fopma; Monique Bomer-Veenboer; Mariángeles Boti; G Danielle E Oosterling; Esther Scholten; Marleen Tollenaere; Laura Checkley; André Strydom; Gert Van Goethem; Graziano Onder; Rafael Blesa; Christine Zu Eulenburg; Antonia M W Coppus; Anne-Sophie Rebillat; Juan Fortea; Peter P De Deyn Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Leonie C P Banning; Inez H G B Ramakers; Paul B Rosenberg; Constantine G Lyketsos; Jeannie-Marie S Leoutsakos Journal: Int J Geriatr Psychiatry Date: 2020-09-11 Impact factor: 3.485
Authors: Jana Janssens; Yannick Vermeiren; Erik Fransen; Tony Aerts; Debby Van Dam; Sebastiaan Engelborghs; Peter P De Deyn Journal: Alzheimers Dement (Amst) Date: 2018-02-06
Authors: John O'Brien; John Paul Taylor; Clive Ballard; Roger A Barker; Clare Bradley; Alistair Burns; Daniel Collerton; Sonali Dave; Rob Dudley; Paul Francis; Andrea Gibbons; Kate Harris; Vanessa Lawrence; Iracema Leroi; Ian McKeith; Michel Michaelides; Chaitali Naik; Claire O'Callaghan; Kirsty Olsen; Marco Onofrj; Rebecca Pinto; Gregor Russell; Peter Swann; Alan Thomas; Prabitha Urwyler; Rimona Sharon Weil; Dominic Ffytche Journal: J Neurol Neurosurg Psychiatry Date: 2020-03-25 Impact factor: 10.154